Cargando…

A Case of Immune Thrombocytopenia After BNT162b2 mRNA COVID-19 Vaccination

Patient: Female, 39-year-old Final Diagnosis: Immune thrombocytopenic purpura Symptoms: Purpuric skin lesions • thrombocytopenia Medication: — Clinical Procedure: None Specialty: Hematology • Immunology OBJECTIVE: Unusual clinical course BACKGROUND: Immune thrombocytopenic purpura (ITP) is an immune...

Descripción completa

Detalles Bibliográficos
Autores principales:	King, Eleanor R., Towner, Elizabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Scientific Literature, Inc. 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311388/ https://www.ncbi.nlm.nih.gov/pubmed/34285180 http://dx.doi.org/10.12659/AJCR.931478

Ejemplares similares

Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
por: Akiyama, Hiroaki, et al.
Publicado: (2021)

Vaccine-induced immune thrombotic thrombocytopenia after the BNT162b2 mRNA Covid-19 vaccine: A case study
por: Rodríguez, Carmen, et al.
Publicado: (2021)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Safety and BNT162b2 mRNA COVID-19 vaccination
por: Joob, Beuy, et al.
Publicado: (2021)

Vaccine-Induced Immune Thrombotic Thrombocytopenia following BNT162b2 mRNA COVID-19 Booster: A Case Report
por: Lin, Tzu-Chien, et al.
Publicado: (2023)

Specific immune responses after BNT162b2 mRNA vaccination and COVID-19 infection
por: Arientová, Simona, et al.
Publicado: (2023)

Pericarditis after administration of the BNT162b2 mRNA COVID-19 vaccine
por: Ramírez-García, Almudena, et al.
Publicado: (2021)

Aseptic meningitis after vaccination of the BNT162b2 mRNA COVID-19 vaccine
por: Saito, Kazuyuki, et al.
Publicado: (2021)

New onset of hypomegakaryocytic thrombocytopenia with the potential for progression to aplastic anemia after BNT162b2 mRNA COVID-19 vaccination
por: Kobayashi, Mirei, et al.
Publicado: (2023)

Systems biological assessment of human immunity to BNT162b2 mRNA vaccination
por: Arunachalam, Prabhu S., et al.
Publicado: (2021)

BNT162b2 mRNA COVID-19 vaccine Reactogenicity: The key role of immunity
por: Vizcarra, Pilar, et al.
Publicado: (2021)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
por: Polack, Fernando P., et al.
Publicado: (2020)

BNT162b2 mRNA COVID-19 Vaccine: First Approval
por: Lamb, Yvette N.
Publicado: (2021)

Dermatomyositis Following BNT162b2 mRNA COVID-19 Vaccination
por: Gouda, Wesam, et al.
Publicado: (2022)

Myopericarditis After BNT162b2 mRNA Vaccination With Incidental Intramyocardial Bridging
por: Elghazal, Mohamed, et al.
Publicado: (2023)

Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
por: Kitagawa, Hiroki, et al.
Publicado: (2022)

Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel
por: Mevorach, Dror, et al.
Publicado: (2021)

Rhabdomyolysis after BNT162b2 mRNA Covid-19 vaccine in an adolescent male
por: Sutcu, Murat, et al.
Publicado: (2022)

BNT162b2 mRNA Vaccine–Induced Immune Response in Oral Fluids and Serum
por: Seneviratne, Chaminda Jayampath, et al.
Publicado: (2022)

Adaptive immune response to BNT162b2 mRNA vaccine in immunocompromised adolescent patients
por: Bader, Guy, et al.
Publicado: (2023)

The Peripheral Immune Landscape in a Patient with Myocarditis after the Administration of BNT162b2 mRNA Vaccine
por: Yoon, Bo Kyung, et al.
Publicado: (2022)

Delayed large pruritic eruption to the BNT162b2 mRNA vaccine
por: Terashima, Takeshi
Publicado: (2021)

Central serous chorioretinopathy following the BNT162b2 mRNA vaccine
por: Hanhart, J., et al.
Publicado: (2022)

Addendum: Systems vaccinology of the BNT162b2 mRNA vaccine in humans
por: Arunachalam, Prabhu S., et al.
Publicado: (2023)

BNT162b2 mRNA Vaccine Interference with Co-Administration of Tdap Vaccine
por: Chilimuri, Sridhar, et al.
Publicado: (2021)

Unusual lymphadenopathies secondary to the BNT162b2 mRNA Covid-19 vaccine
por: Felices-Farias, Jose Manuel, et al.
Publicado: (2022)

Safety and effectiveness of BNT162b2 mRNA Covid-19 vaccine in adolescents
por: June Choe, Young, et al.
Publicado: (2022)

Unusual lymphadenopathies secondary to the BNT162b2 mRNA Covid-19 vaccine
por: Felices-Farias, Jose Manuel, et al.
Publicado: (2022)

Hemophagocytic Lymphohistiocytosis Following BNT162b2 mRNA COVID-19 Vaccination
por: Lin, Ting-Yu, et al.
Publicado: (2022)

Erythema nodosum triggered by BNT162b2 mRNA COVID-19 vaccine
por: Juddoo, Vanessa, et al.
Publicado: (2022)

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
por: Thompson, Mark G., et al.
Publicado: (2021)

Cardiovascular Manifestation of the BNT162b2 mRNA COVID-19 Vaccine in Adolescents
por: Mansanguan, Suyanee, et al.
Publicado: (2022)

Acute myocarditis after receiving first dose of BNT162b2 mRNA vaccine
por: Wu, Bryan, et al.
Publicado: (2022)

Bilateral anterior uveitis after BNT162b2 mRNA vaccine: Case report
por: Duran, M.
Publicado: (2022)

Blood Antibody Titers and Adverse Reactions after BNT162b2 mRNA Vaccination
por: Kiewisz, Jolanta, et al.
Publicado: (2022)

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
por: Payne, Rebecca P., et al.
Publicado: (2021)

Cerebral Venous Sinus Thrombosis After BNT162b2 mRNA COVID-19 Vaccination
por: Yamaguchi, Yoshitaka, et al.
Publicado: (2021)

Adult-onset Still’s Disease after BNT162b2 mRNA COVID-19 Vaccine
por: Park, Seong Yeon, et al.
Publicado: (2021)

Case report of Guillain-Barré Syndrome after COVID BNT162b2 mRNA vaccine()
por: Sosa-Hernández, Oscar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_naqmi9vpj8v4cl4tkm2j1gfgft